Are bone targeted agents still useful in times of immunotherapy? The SAKK 80/19 BTA pilot study

Background: Patients with bone metastases from solid tumors often have additional treatment with bone targeted agents (BTAs) to avoid symptomatic skeletal events (SSEs) such as clinically significant pathological fracture leading toradiation therapy or surgery to the bone, spinal cord compression, o...

Descripció completa

Dades bibliogràfiques

Autors principals:	Michael Mark, Alfonso Rojas Mora, Thomas Winder, Anastasios Stathis, Andreas Jakob, Gisela Müller, Stefanie Hayoz, Patrick Reimann, Ulf Petrausch, Roger von Moos
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2024-09-01
Col·lecció:	Bone Reports
Matèries:	Bone metastases Bone-targeting agents Skeletal-related events Symptomatic skeletal events Immunotherapy
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2352187224000615
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!